Cytoreductive Surgery may be beneficial for highly selected patients with Metastatic Gastrointestinal Stromal Tumors receiving Regorafenib facing Local Progression: A Case Controlled Study

Background: Current evidence have shown surgery may provide progression-free survival (PFS) benefit for selected patients with metastatic gastrointestinal stromal tumor (GIST) who received first line imatinib and second line sunitinib. However, impact of cytoreductive surgery for GIST patients recei...

Descripción completa

Detalles Bibliográficos
Autores principales: Yeh, Chun-Nan, Hu, Chia-Hsiang, Wang, Shang-Yu, Wu, Chiao-En, Chen, Jen-Shi, Tsai, Chun-Yi, Hsu, Jun-Te, Yeh, Ta-Sen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2021
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8100794/
https://www.ncbi.nlm.nih.gov/pubmed/33976743
http://dx.doi.org/10.7150/jca.50324

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8100794/
https://www.ncbi.nlm.nih.gov/pubmed/33976743
http://dx.doi.org/10.7150/jca.50324

Ejemplares similares